Prurisol has similar potential, reflecting the rising value of oral therapies in treating psoriasis. The drug already has performed comparably to Otezla when it was at a similar stage of development. In the current clinical trial, a Phase 2b assessing moderate-to-severe psoriasis, Prurisol might show even greater efficacy after an evaluation of higher dosing regimens, 300mg and 400mg respectively.
“Among systemic-naïve patients with moderate-to-severe psoriasis, there were no statistically significant differences between apremilast and methotrexate. In addition, the [incremental cost per responder] with apremilast vs. methotrexate is high. … These results could provide clinically and economically relevant implications for health care decision makers.”
"As conveyed by Cellceutix management in a presentation given at the 2017 Biotech Showcase held in San Francisco, CA, the company’s focus this year is on partnerships—identifying new opportunities as well as continuing discussions with companies already under Confidential Disclosure Agreement (CDA)."
"With a number of upcoming anticipated clinical milestones (see below), management is hopeful that partnerships can be struck in 2017 to help advance Cellceutix's pipeline of First-in-Class drug candidates—Prurisol, Kevetrin and Brilacidin—toward market approval."
News 
Market Data 
Discover 
